Premium
Effect of a prostaglandin EP4 receptor agonist on early fixation of hydroxyapatite/titanium composite‐ and titanium‐coated rough‐surfaced implants in ovariectomized rats
Author(s) -
Hayashi K.,
Fotovati A.,
Ali S. Abu,
Nakamura Y.,
Inagaki M.,
Naito M.
Publication year - 2009
Publication title -
journal of biomedical materials research part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 150
eISSN - 1552-4965
pISSN - 1549-3296
DOI - 10.1002/jbm.a.32444
Subject(s) - ovariectomized rat , agonist , materials science , implant , titanium , saline , osteoporosis , fixation (population genetics) , receptor , dentistry , biomedical engineering , endocrinology , medicine , surgery , metallurgy , population , estrogen , environmental health
The agonist of the prostaglandin EP4 receptor can increase bone density in osteoporosis. Using ovariectomized (OVX) and sham‐operated (SO) rats, the effects of the EP4 receptor agonist, ONO‐4819, and hydroxyapatite (HA) on implant‐bone fixation in implants with a rough surface were investigated. Female Wistar rats (12 weeks old) were divided into either SO or bilateral OVX groups. Twenty four weeks later, either hydroxyapatite/titanium (HA/Ti) composite‐coated or Ti‐coated implants were implanted into the femora, and the animals were treated with either ONO‐4819 or saline for 4 weeks. The fixation strength of the HA/Ti‐coated implants was higher than that of the Ti‐coated implants in the saline‐treated OVX rats. In the OVX rats, ONO‐4819 enhanced fixation of the rough Ti‐coated implants to levels similar to that of HA/Ti‐coated implants. These data suggest that a combination of treatment with an EP4 receptor agonist and a rough‐surfaced implant might be useful in increasing the early fixation of cement‐less arthroplasty, particularly in elderly patients with osteoporosis. © 2009 Wiley Periodicals, Inc. J Biomed Mater Res, 2010